183 related articles for article (PubMed ID: 11552225)
1. Pharmacokinetic profiles of doxorubicin in combination with taxanes.
Holmes FA; Rowinsky EK
Semin Oncol; 2001 Aug; 28(4 Suppl 12):8-14. PubMed ID: 11552225
[TBL] [Abstract][Full Text] [Related]
2. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
Sparano JA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):14-9. PubMed ID: 10426454
[TBL] [Abstract][Full Text] [Related]
4. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Sparano JA
Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Valero V; Perez E; Dieras V
Semin Oncol; 2001 Aug; 28(4 Suppl 12):15-23. PubMed ID: 11552226
[TBL] [Abstract][Full Text] [Related]
6. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
Gianni L; Viganò L; Locatelli A; Capri G; Giani A; Tarenzi E; Bonadonna G
J Clin Oncol; 1997 May; 15(5):1906-15. PubMed ID: 9164201
[TBL] [Abstract][Full Text] [Related]
7. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y
Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
Nabholtz JM; North S; Smylie M; Mackey J; Au HJ; Au R; Morrish D; Salter E; Tonkin K
Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin in combination with the taxanes.
Trudeau M; Pagani O
Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Nabholtz JM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
[TBL] [Abstract][Full Text] [Related]
11. Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel.
Briasoulis E; Karavasilis V; Tzamakou E; Rammou D; Soulti K; Piperidou C; Pavlidis N
Cancer Chemother Pharmacol; 2004 May; 53(5):452-7. PubMed ID: 14749894
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
[TBL] [Abstract][Full Text] [Related]
14. Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
Dieras V
Semin Oncol; 1998 Oct; 25(5 Suppl 12):18-22. PubMed ID: 9865707
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
Zeng S; Chen YZ; Fu L; Johnson KR; Fan W
Clin Cancer Res; 2000 Sep; 6(9):3766-73. PubMed ID: 10999771
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
Buzdar AU; Holmes FA; Hortobagyi GN
Semin Oncol; 1995 Jun; 22(3 Suppl 6):101-4. PubMed ID: 7541151
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
[TBL] [Abstract][Full Text] [Related]
18. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
Nabholtz JM; Tonkin K; Smylie M; Mackey J; Janowska-Wieczorek A
Semin Oncol; 1999 Feb; 26(1 Suppl 3):10-6. PubMed ID: 10203265
[TBL] [Abstract][Full Text] [Related]
19. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Radaideh SM; Sledge GW
Breast Cancer Res Treat; 2008 Sep; 111(2):203-8. PubMed ID: 17990102
[TBL] [Abstract][Full Text] [Related]
20. Taxoids in combination chemotherapy for metastatic breast cancer.
Dieras V; Fumoleau P; Bourgeois H; Misset JL; Azli N; Pouillart P
Anticancer Drugs; 1996 Aug; 7 Suppl 2():47-52. PubMed ID: 8862712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
